Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 5 studies | 76% ± 13% | |
endothelial cell | 3 studies | 18% ± 1% | |
neutrophil | 3 studies | 28% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 37% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 27467.50 | 226 / 226 | 95% | 86.29 | 385 / 406 |
intestine | 40% | 542.05 | 388 / 966 | 82% | 12.28 | 434 / 527 |
stomach | 42% | 289.81 | 150 / 359 | 78% | 11.43 | 222 / 286 |
kidney | 90% | 2970.06 | 80 / 89 | 26% | 4.11 | 233 / 901 |
lung | 73% | 493.39 | 422 / 578 | 42% | 31.07 | 487 / 1155 |
esophagus | 40% | 1982.29 | 578 / 1445 | 72% | 34.58 | 131 / 183 |
bladder | 48% | 589.48 | 10 / 21 | 59% | 12.79 | 295 / 504 |
spleen | 98% | 1955.56 | 236 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 87% | 5631.65 | 810 / 929 | 0% | 0 | 0 / 0 |
pancreas | 3% | 8.40 | 10 / 328 | 77% | 13.22 | 137 / 178 |
skin | 70% | 551.89 | 1260 / 1809 | 1% | 0.03 | 3 / 472 |
uterus | 5% | 64.04 | 8 / 170 | 51% | 13.11 | 232 / 459 |
tonsil | 0% | 0 | 0 / 0 | 51% | 6.71 | 23 / 45 |
ovary | 1% | 3.16 | 2 / 180 | 37% | 2.83 | 159 / 430 |
brain | 12% | 49.40 | 324 / 2642 | 14% | 1.41 | 99 / 705 |
prostate | 22% | 104.25 | 55 / 245 | 1% | 0.03 | 4 / 502 |
breast | 1% | 4.94 | 5 / 459 | 10% | 0.82 | 107 / 1118 |
adipose | 8% | 44.73 | 101 / 1204 | 0% | 0 | 0 / 0 |
thymus | 1% | 3.44 | 9 / 653 | 2% | 0.60 | 10 / 605 |
adrenal gland | 2% | 5.35 | 5 / 258 | 0% | 0.03 | 1 / 230 |
heart | 2% | 6.04 | 15 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 1% | 5.68 | 19 / 1335 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.34 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006690 | Biological process | icosanoid metabolic process |
GO_0006691 | Biological process | leukotriene metabolic process |
GO_0019369 | Biological process | arachidonic acid metabolic process |
GO_0036101 | Biological process | leukotriene B4 catabolic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0097258 | Molecular function | 20-hydroxy-leukotriene B4 omega oxidase activity |
GO_0004497 | Molecular function | monooxygenase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0020037 | Molecular function | heme binding |
GO_0070330 | Molecular function | aromatase activity |
GO_0097259 | Molecular function | 20-aldehyde-leukotriene B4 20-monooxygenase activity |
GO_0050051 | Molecular function | leukotriene-B4 20-monooxygenase activity |
Gene name | CYP4F3 |
Protein name | Cytochrome P450 family 4 subfamily F member 3 Cytochrome P450 4F3 (EC 1.14.14.1) (20-hydroxyeicosatetraenoic acid synthase) (20-HETE synthase) (CYPIVF3) (Cytochrome P450-LTB-omega) (Docosahexaenoic acid omega-hydroxylase CYP4F3) (EC 1.14.14.79) (Leukotriene-B(4) 20-monooxygenase 2) (Leukotriene-B(4) omega-hydroxylase 2) (EC 1.14.14.94) |
Synonyms | LTB4H |
Description | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) . May play a role in inactivation of pro-inflammatory and anti-inflammatory oxylipins during the resolution of inflammation . .; FUNCTION: [Isoform CYP4F3A]: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of oxylipins in myeloid cells, displaying higher affinity for arachidonate metabolite leukotriene B4 (LTB4) . Inactivates LTB4 via three successive oxidative transformations to 20-hydroxy-LTB4, then to 20-oxo-LTB4 and to 20-carboxy-LTB4 . Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate . Omega-hydroxylates monohydroxy polyunsaturated fatty acids (PUFAs), including hydroxyeicosatetraenoates (HETEs) and hydroxyeicosapentaenoates (HEPEs), to dihydroxy compounds . Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acid, thereby initiating chain shortening . Has low hydroxylase activity toward PUFAs . .; FUNCTION: [Isoform CYP4F3B]: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of polyunsaturated fatty acids (PUFAs) . Participates in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure . Has high omega-hydroxylase activity toward other PUFAs, including eicosatrienoic acid (ETA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) . Can also catalyze the oxidation of the penultimate carbon (omega-1 oxidation) of PUFAs with lower efficiency . Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid and hexacosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acids, thereby initiating chain shortening . Omega-hydroxylates long-chain 3-hydroxy fatty acids, likely initiating the oxidative conversion to the corresponding 3-hydroxydicarboxylic fatty acids . Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate . . |
Accessions | V9GYA1 Q08477 ENST00000221307.13 [Q08477-1] ENST00000586182.6 [Q08477-2] ENST00000587360.1 ENST00000585846.1 [Q08477-2] ENST00000591058.5 [Q08477-2] ENST00000592424.1 K7EJZ8 |